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Abstract:  Identification of patient characteristics influencing treatment outcomes is a top low back pain 
(LBP) research priority. Results from the STarT Back Trial support the effectiveness of prognostic 
stratified care for LBP compared to current best care, however patient characteristics associated with 
treatment response have not yet been explored. The purpose of this secondary analysis was to identify 
treatment-effect modifiers within the STarT Back Trial at 4 months follow-up (n=688). Treatment 
response was dichotomized using back-specific physical disability measured by the Roland-Morris 
Disability Questionnaire (≥7). Candidate modifiers were identified using previous literature and evaluated 
using logistic regression with statistical interaction terms to provide preliminary evidence of treatment-
effect modification. Socioeconomic status (SES) was identified as an effect modifier for disability 
outcomes (OR = 1.71, P=.028). High SES patients receiving prognostic stratified care were 2.5 times less 
likely to have a poor outcome compared to low SES patients receiving best current care (OR = 0.40, 
P=.006). Education level (OR = 1.33, P=.109) and number of pain medications (OR = 0.64, P=.140) met 
our criteria for effect modification with weaker evidence (0.20>P≥0.05). These findings provide 
preliminary evidence for SES, education, and number of pain medications as treatment-effect modifiers of 
prognostic stratified care delivered in the STarT Back Trial. 
 
Perspective:  This analysis provides preliminary exploratory findings about the characteristics of patients 
who might least likely benefit from targeted treatment using prognostic stratified care for low back pain. 
 
Keywords:  low back pain, socioeconomic status, treatment effect modification, stratified care, 
subgrouping 
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Background 
Identification of patients that are most likely to positively respond or gain the greatest benefit from 
different treatment approaches has been indicated as a top low back pain (LBP) research priority.15, 18, 60  
The STarT Back trial36 evaluated the clinical and cost effectiveness of stratified primary care that 
involved targeting treatment to subgroups based on their prognostic risk of persistent disabling pain.36  
The trial results were favorable for the overall comparison between stratified care compared to current 
best practice at both 4 and 12 month follow-ups and for the comparison between patients at low, medium 
and high risk of persistent pain in each arm of the trial.36 In this paper, we focus on identifying the 
characteristics of patients who benefitted the most (and least) from this stratified care approach.   
 
Identifying which patient level variables influence treatment outcomes has the potential to enhance 
clinical reasoning.30 Methodological recommendations for study design, analysis and interpretation of 
such subgroup analyses are available including the need for clear terminology.7, 41, 59, 65, 69  In this study we 
attempt to distinguish between variables that demonstrated treatment effect modification for stratified care 
outcomes from those that were predictive of patient outcomes regardless of treatment. We use treatment 
effect modifiers are used for variables measured at baseline that demonstrated an interaction with the 
stratified care treatment outcomes (ie. in whom treatment was least effective).44, 59 For example, other 
study findings suggest older age as a potential treatment effect modifier for chronic LBP patients 
receiving Mechanical Diagnosis and Therapy (ie, McKenzie method) compared to Back School, 
indicating age may be an important factor to consider when identifying responders to this specific 
treatment.24 We use prognostic factors for variables measured at baseline that were predictive of patient 
outcomes but did not interact with allocated treatment and were therefore not providing information 
specific to the stratified care intervention response.44, 59 For example, psychological factors have been 
found to be strong prognostic indicators for LBP outcomes, however not consistently predictive of 
response to physical therapist-led exercise and/or advice (ie, a specific treatment).68  
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Most clinical trials are not adequately powered to investigate subgroup effects, however such analyses 
can still provide important hypothesis-generating information for future research.44, 59  Pincus et al.59 
recommend four key criteria for treatment effect modification analysis using clinical trial data: 1) 
potential modifiers should be measured prior to randomization; 2) selection of potential modifiers should 
be based on theory or evidence; 3) measurement of baseline factors should be reliable and valid; and 4) an 
explicit test of the interaction between potential modifiers and treatment is required. Gurung et al.28 
recently used these criteria in their systematic review of potential LBP treatment effect modifiers from 
four clinical trials, testing acupuncture,12, 78  exercise and manual therapy,71 and psychological treatment.46 
Variables associated with treatment outcome that had strong evidence included patients’ age, employment 
status and type, back pain severity, narcotic medication use, treatment expectations and education level. 
Variables associated with treatment outcome that had weak evidence included gender, psychological 
distress, initial pain intensity, disability, and quality of life.   
 
STarT Back trial36 patient characteristics that interact with treatment outcome have not yet been evaluated 
and these have the potential to provide additional information about which patients might be less likely to 
benefit from matched treatment in this stratified care approach. Therefore, the purpose of this analysis 
was to explore potential patient level treatment effect modifiers at four months follow-up. Specifically, 
our strategy was twofold consisting of: 1) identification of potential treatment effect modification using 
descriptive statistics to explore the patient characteristics associated with treatment outcome in which 
there was no benefit from stratified care and 2) preliminary confirmation of treatment effect modification 
using formal moderation analysis with a test for statistical interaction.  
 
Methods 
STarT Back Trial 
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We conducted a secondary analysis of data from the STarT Back trial.36 Briefly, the STarT Back trial was 
a parallel, two-armed, randomized controlled trial that evaluated the clinical and cost effectiveness of 
prognostic risk stratified primary care (intervention) with non-stratified current best care (control) for 
LBP patients with follow-up at 4 and 12 months. Participants were recruited from 10 general practices in 
the North West Midlands region of England, UK.      
 
STarT Back Trial Procedures 
All participants received an initial 30-minute physical therapy evaluation that was supplemented with a 
brief intervention consisting of LBP education and advice. Subsequent interventions were based on 
participant randomized allocation. Additional treatment for control group participants was at the 
discretion of the treating physical therapist, as per current best care. Additional treatment for intervention 
group participants was based on baseline risk stratification (low, medium, or high risk for persistent LBP 
disability) determined using the STarT Back tool.34  Details of the matched treatments have previously 
been described elsewhere.31 
 
Description of Candidate Treatment Effect Modifiers 
Baseline factors were collected from each participant prior to randomization and treatment allocation. 
Selection of potential treatment effect modifiers for this secondary analysis was based on their influential 
relationship with LBP clinical outcome as indicated by previous literature (defined below). For this 
analysis we focused only on treatment modifiers that would not be expected to change during treatment 
and therefore could be used to characterize patients. Other factors such as pain intensity or psychological 
variables that were specifically targeted through stratified care interventions and therefore expected to 
change were not included based on a priori determination. The selected treatment effect modifiers are 
described below with the hypothesized direction of influence defined for each factor. 
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1. Age was categorized into one of three groups (≤ 44; 45-64; ≥65 years) similar to previous studies.62  
We hypothesized that prognostic stratified care would be less effective compared to best current care 
for older (≥65 years) compared to younger patients.28, 32, 46, 63, 66, 76   
2. Gender was categorized into one of two groups (female or male). We hypothesized that prognostic 
stratified care would be less effective compared to best current care for females compared to males 
after controlling for baseline disability based on findings from previous review studies.3, 21  
3. Education level was categorized into one of four groups (further or higher education, other work or 
non-work related, compulsory education, or no qualifications).57 Further education includes all non-
advanced courses taken after the period of compulsory education including secondary school, 
whereas higher education is beyond secondary school commonly offered at the university level. Other 
work or non-work related education includes other types of non-school, non-university education and 
training. Compulsory education is required for all children between 5 and 16 years of age. We 
hypothesized that prognostic stratified care would be less effective compared to current best care for 
patients with lower levels of education.8, 16, 28, 46   
4. Socioeconomic status (SES) was assessed using the National Statistics Socio-economic Classification 
(NS-SEC) reduced method which is primarily based on job occupation.56  Categorization was solely 
based on job occupation. The NS-SEC was collapsed into one of three classes of SES (Upper [higher 
managerial, administrative and professional occupations]; Middle [intermediate occupations]; and 
Lower [lower supervisory and technical occupations, semi-routine and routine occupations]). We 
hypothesized that prognostic stratified care would be less effective compared to current best care for 
patients with lower SES.8-10, 52  
5. Current employment status was dichotomized (yes or no). We hypothesized that prognostic stratified 
care would be less effective compared to current best care for patients that were not currently 
employed.27, 28, 46, 52, 76   
6. Work satisfaction was dichotomized (satisfied or not satisfied) based on responses to a five-point 
Likert scale. ‘Very satisfied’ and ‘satisfied’ responses were collapsed to create a ‘satisfied’ variable 
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and ‘no opinion’, ‘not very satisfied’, and ‘not at all satisfied’ responses were collapsed to create a 
‘not satisfied’ variable. We hypothesized that prognostic stratified care would be less effective 
compared to current best care for patients that were not satisfied with their work.14, 47, 50 
7. Duration of current symptoms was categorized into one of three groups (<1 month; 1 to 3 months; or 
>3 months). We hypothesized that prognostic stratified care would be less effective compared to 
current best care for patients that reported a longer duration of symptoms.33, 63, 66, 76 
8. Number of current pain medications was categorized into one of three groups (0; 1 to 2; ≥3). We 
hypothesized that prognostic stratified care would be less effective compared to current best care for 
patients that reported using three or more pain medications.23, 25, 26, 38, 51, 61 
9. Expectations for recovery at  four months was categorized into one of three groups (high, moderate, 
low) based on tertile cutoff scores from  an 11-point scale with ‘0’ indicating ‘completely better’ to 
‘10’ indicating ‘extreme pain’. We hypothesized that prognostic stratified care would be less effective 
compared to best current care for patients reporting lower expectations for recovery.4, 8, 22, 28, 33, 54   
  
Definition of Outcome 
We defined outcome as LBP related physical disability at four months following randomization assessed 
using the Roland and Morris Disability Questionnaire (RMDQ).64 The 24-item RMDQ assesses physical 
function over the past 24 hours and has a potential scoring range of 0 ‘no disability due to LBP’ to 24 
‘maximum disability due to LBP’, with higher scores indicating higher LBP related disability. The 
RMDQ has been found to have high levels of test-retest reliability, internal consistency, validity, and 
responsiveness.11 To be consistent with previous research involving the STarT Back screening tool34, 77 
disability outcome scores at four months were recoded into Satisfactory Outcome (RMDQ <7) and Poor 
Outcome (RMDQ ≥7). Our rationale for analyzing LBP related disability outcomes at 4 months was based 
on detection of larger between group effect sizes in the STarT Back trial at this time-point,36 therefore 
identification of treatment effect modifiers was more likely at 4 months compared to 12 months. 
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Data Analysis 
All statistical analyses were performed using IBM SPSS version 22.0 (IBM Corp, Armonk, New York). 
Descriptive statistics were used to evaluate for treatment effect modification within and between baseline 
factors and treatment allocation (ie, stratified care versus best current care) for disability outcome. Chi-
square testing was used to compare the proportion of patients with poor outcome (RMDQ ≥7) across 
treatment groups at each level of individual baseline factors to provide an indication of potential treatment 
effect modification from stratified care. Specifically, we were interested in potential modifiers associated 
with a greater proportion of patients with poor outcome for the stratified care group compared to best 
current care (P<.05), which would potentially provide an indication of treatment effect modification.      
 
Once potential treatment effect modifiers were identified from the above descriptive analysis, they were 
confirmed with a formal moderation analysis using a test for statistical interaction.59, 69 We fully 
acknowledge that our sample size may not be adequately powered for these statistical interaction tests 
following guidance on minimal group size,59 therefore the results should only be interpreted as 
preliminary. Separate binary logistic regression models were used to evaluate contributions of each 
individual baseline potential treatment effect modifier and treatment group allocation. We tested for 
treatment modification by incorporating a group x factor interaction term. Specifically, each model was 
built using three separate blocks: 1) baseline RMDQ score and treatment group; 2) baseline factor; 3) 
treatment group x baseline factor interaction term. All interactions with a p-value ≤0.20 were reported to 
ensure all possible treatment effect modifiers were identified and categorized into exploratory (P<0.05) or 
additional exploratory evidence (0.20>P≥0.05) similar to criteria used for a recent systematic review.28  
 
Results 
Baseline characteristics of participants are described in Table 1. 
Potential Treatment Effect Modifiers 
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The results from the descriptive analysis demonstrated, as expected, that there were similar and consistent 
within treatment arm relationships between several baseline potential treatment effect modifiers and the 
proportion of patients with poor outcome.  General prognostic factors with an increased proportion of 
patients with a poor outcome in both stratified care and best current care groups included; older age, 
lower level of education, greater number of pain medications, and lower expectations for recovery (Table 
2).   Inspection of the between treatment arm comparisons generally and consistently revealed a higher 
proportion of best current care patients associated with poor outcome (in favor of stratified care), however 
there were several baseline factors where the proportion of stratified care patients associated with poor 
outcome was similar between treatment arms (P >.05) indicating stratified care did not benefit and 
signifying potential treatment effect modification (ie, lower education, low SES, lack of current 
employment, >=3 pain medications, and low expectations for recovery) (Table 2). Each factor associated 
with non-significant (P > .05) between treatment arm relationships was selected for subsequent formal 
moderation analysis to test for statistical interactions using logistic regression. 
 
Exploratory Evidence for Treatment Effect Modification 
The results of the logistic regression are provided in Table 3. Socioeconomic status (SES) was identified 
as the only treatment effect modifier for poor treatment outcome (RMDQ ≥7) at four months (OR = 1.71, 
95% CI: 1.06, 2.77, P = .028) (Figure 1). Decomposition of the treatment x SES interaction term 
indicated that compared to those receiving best current care with low SES, those receiving stratified care 
with high SES were 2.5 times less likely to have a poor treatment outcome (OR = 0.40, 95% CI: 0.20, 
0.77, P = .006) (Figure 2). Further exploratory descriptive analysis indicated a greater proportion of low 
SES patients with poor treatment outcome that received stratified care compared to best current care for 
low (13.0% and 9.5%) and medium (33.7% and 25.0%) risk subgroups, however this was not observed 
for the high risk subgroup (55.0% and 69.7%) and needs to be interpreted with caution as cell counts were 
very low. Similar trends were also observed for patients with low education (ie, no qualifications) for low 
(18.8% and 11.1%), medium (37.0% and 36.8%) and high (73.3% and 71.3%) risk subgroups.   There 
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were no other STarT Back risk groups for whom stratified care produced worse treatment outcomes than 
those receiving current best care. 
 
Additional Exploratory Evidence for Treatment Effect Modification  
Other treatment effect modifiers meeting our criteria for treatment effect modification with additional 
exploratory evidence (0.20>P≥0.05) included education level (OR = 1.33, 95% CI: 0.94, 1.90, P = .109) 
(Figure 3) and number of current pain medications (OR = 0.64, 95% CI: 0.35, 1.16, P = .140) (Figure 4). 
Decomposition of the treatment x education interaction term indicated that compared to those receiving 
best current care with ‘no qualifications’, those receiving stratified care who had ‘further or higher 
education’ were approximately 3 times less likely to have a poor treatment outcome (OR = 0.30, 95% CI: 
0.14, 0.63, P = .002). Decomposition of the treatment x pain medication interaction term indicated that 
compared to those receiving best current care who were using ‘≥3 pain medications’, those receiving 
stratified care and using ‘no pain medications’ were approximately 5 times less likely to have a poor 
treatment outcome (OR = 0.19, 95% CI: 0.08, 0.45, P < .001). 
 
Comparative Moderation Analysis Findings 
Additional support for treatment effect modification was reduced when performing similar moderation 
analyses using linear regression with either RMDQ percent change or continuous scale scores  at four 
months serving as the dependent variable in separate models (complete data not provided).  Specifically, 
observed treatment x SES statistical interaction p-values changed from 0.028 (RMDQ ≥7 model) to 0.066 
(RMDQ percent change score model) and 0.072 (RMDQ continuous scale score model). 
 
Discussion 
Statement of Principal Findings 
The aim of this secondary analysis was to explore for baseline patient level treatment effect modifiers for 
stratified care within the STarT Back trial, with a focus on those that were associated with a poor 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
treatment outcome. We found that stratified care was associated with fewer patients of high SES with 
poor outcome (19.3%) compared to best current care (38.9%).  However, in patients categorized as low 
SES the proportion with poor outcome was similar (35.4% and 37.2%).  Treatment effect modification 
was statistically significant (P = .028) for SES and decomposition of the interaction indicated that 
compared to those receiving best current care who were classed as low SES, those receiving stratified 
care classed as high SES were 2.5 times less likely to have a poor treatment outcome. This finding is 
consistent with previous studies that have reported treatment effect modification by SES for other health 
conditions.48  Weaker evidence for treatment effect modification was found for education and number of 
pain medications, which although consistent with previous findings, require further exploration in 
adequately powered studies.  
 
Socioeconomic Status 
The observation in this exploratory analysis that the proportion of low SES patients with poor outcome 
was very similar in both treatment arms of the trial (35.4% and 37.2%) is of potential clinical importance. 
Although we were not able to definitively determine if stratified care was more beneficial for high SES 
participants or less beneficial for low SES participants, two plausible theories may provide explanation of 
the potential influence of SES. First, lower SES patients did not beneficially respond to stratified care (ie, 
the matched treatments were not sufficiently tailored for lower SES patients, particularly it would seem 
from descriptive data only, in the STarT Back Tool’s low and medium risk subgroups). Previous 
suggestions have indicated that increased patient commitment, motivation and potentially more intensive 
treatment may be required for patients at high risk with other health conditions.45 It is also plausible that 
barriers to good health outcomes commonly encountered by low SES patients (eg. low health literacy, 
poorer access to care) involve complex interactions at both the environmental and individual level and 
these may have influenced our results.9  Therefore, modifying treatment approaches to meet the needs of 
different SES groups has been previously suggested74 which may have implications for all patients 
regardless of risk status for clinical outcomes.  Second, there is the potential that low SES patients 
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enrolled in the STarT Back trial36 shared similar characteristics to patients that do not respond to LBP 
treatments in general. For example, secondary analysis of data (n = 949) from the UKBEAM trial where 
participants were randomized to receive either 1) best general practice care only or in addition: 2) spinal 
manipulation, 3) exercise or 4) combined spinal manipulation and exercise; found similar findings to our 
study with the intervention showing a  less favorable treatment effect for certain individuals based on 
three SES indicators.52 Specifically, study participants from areas of high deprivation, with less education, 
and who were not working consistently (ie. those with low SES) reported greater LBP related disability 
across all treatment groups.52  
 
Socioeconomic disparities are associated with health inequalities for a variety of conditions including 
musculoskeletal disorders.53, 55  However, SES influence on LBP outcomes has not been extensively 
evaluated,10, 73 particularly in comparison to other health conditions. For example, those with higher SES 
have consistently achieved greater rates of long term abstinence compared to those with lower SES 
following participation in tobacco dependence treatment programs.67, 75  Therefore, it is not surprising that 
alternative or enhanced treatments have been suggested for health conditions19, 39, 74 including LBP 9, 17 
that specifically consider the circumstances of patients with low SES. Previous suggestions have also 
indicated that self-management approaches, particularly those incorporating cognitive behavioral 
principles, may be more appropriate for higher SES individuals.9, 10, 17  Consequently, identifying and 
addressing barriers that low SES patients commonly encounter such as low health knowledge or literacy 6, 
13, 70, 72
 is appealing as it has potential to enhance LBP treatment outcomes for this often underserved 
patient population. 
 
Additional Exploratory Evidence for Treatment Effect Modification 
Treatment effect modification trends were also observed for education and use of pain medication, 
findings similar to a recent systematic review that identified potential moderators for response to LBP 
treatment.28  Gurung, et al.28 identified younger age, being employed or in sedentary occupations, less 
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narcotic medication use, higher levels of education, and greater positive treatment expectations as 
potential treatment effect modifiers for positive LBP treatment response using data generated from four 
randomized trials.  In addition, prognostic capabilities associated with lower education level8, 16, 76 and 
using an increased number of pain medications23, 51 have been reported for musculoskeletal pain clinical 
outcomes in previous studies that have not specifically tested for treatment effect modification. 
Collectively, our findings support the need for further exploration of treatment effect modification 
through adequately powered studies and these should include patient level factors such as education level 
and use of pain medications. 
 
Although we were not able to identify other treatment effect modifiers based on statistical interactions, 
several factors demonstrated prognostic capabilities for both intervention and control group outcomes. 
These findings can inform future LBP intervention studies by providing hypothesis generating 
information and highlight the fundamental nature of prognostic research from identifying priority areas 
for risk stratification to evaluating potential candidate factors that may predict treatment response.37 For 
example, older age was associated with an increased proportion of patients with poor outcome compared 
to younger age, which is consistent with previous LBP prognostic study findings.32, 33, 63, 76 Moreover, 
patients with lower expectations for recovery were more likely to have a poor outcome compared to those 
with higher expectations, and this is also consistent with previous LBP prognostic study findings.8, 29, 42 
 
Strengths and Weaknesses  
We conducted secondary analyses of data from a large randomized controlled trial.36 We selected patient 
level factors as potential treatment effect modifiers based on influential relationships with LBP clinical 
outcomes previously reported in the literature. We acknowledge that certain selected factors did have 
potential to change during the course of treatment (ie, number of pain medications and recovery 
expectations); however including such factors in these analyses would potentially enhance the ability to 
characterize patients at baseline.   
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The aims of this study were exploratory following methodological criteria for moderator analysis 
suggested by Pincus et al.59  Specifically, this current study is a secondary ‘post-hoc’ analysis with 
findings provided for hypothesis generating purposes as there was no pre-specified ‘a-priori’ moderator 
effect size reported in the original trial protocol.  Our exploratory results provide important hypothesis 
generating information for future clinical trials which are needed43 and may have specific implications for 
studies evaluating the clinical effectiveness of stratified care for LBP. Our findings reflect exploratory 
evidence that should be interpreted with caution and not considered as confirmatory as the factors 
selected for this secondary analysis were based on theory and previous research.59 For example, lower 
education level8, 16, 76 and increased number of pain medications23, 51 have demonstrated prognostic 
capabilities for musculoskeletal pain related clinical outcomes in previous studies, however were only 
identified as having weak evidence to modify treatment response in our analysis.  Future studies are 
required to confirm these findings prior to changes in clinical practice. 
 
We were not adequately powered to analyze the influence of three-way interactions on poor outcome, 
which is disappointing as those findings may have provided further perspective to our findings.  For 
example, incorporating three-way [treatment x SES x initial STarT Back tool risk subgroup] interaction 
terms into our logistic regression models may have provided preliminary support for stratified care being 
least effective for those patients at low SES also identified as at high risk of persistent pain. Therefore, we 
were not able to fully establish if stratified care was more beneficial for high SES participants or less 
beneficial for low SES participants and if so how these relationships were potentially influenced by other 
factors (eg, risk subgroup, work satisfaction, recovery expectations).  Previous suggestions are that there 
should be a minimum of at least 20 individuals in the smallest group when conducting subgroup 
analyses59 and many cell counts in this current study did not achieve this criterion when comparing the 
proportion of patients with poor outcome by SES across initial risk subgroup (or other factors included in 
these analyses). 
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We also acknowledge the relative strengths and weaknesses associated with our analyses that used an 
absolute cut point (≥7) as opposed to RMDQ change scores and the potential effect this may have on our 
conclusions.  Our decision for using the ≥7 RMDQ cut point allows for direct comparisons to previous 
studies,34, 77 while also considering the optimal method for analyzing responsiveness to LBP interventions 
is debatable. Recent recommendations include reporting the cumulative distribution of responses for 
treatment and control groups to provide the proportion of patients at each scale score who experience 
change at that level or better,18 however such an approach may be difficult to interpret group interactions. 
Others have suggested 30% improvement from baseline to be a useful threshold for identifying clinically 
meaningful improvement,58 however these methods are also associated with limitations.20 Our decision to 
use an absolute cut point is consistent with previous studies involving the STarT Back Tool34, 77 and is a 
common method to assess LBP recovery,40 however may be associated with several limitations including 
loss of statistical power and increased potential for type I and II errors.37 Moreover, we were not able to 
determine if patient perspectives of poor outcome at 4 months was consistent with the RMDQ cut point 
used in this study.        
 
For this secondary analysis, SES was assessed using the National Statistics Socio-economic Classification 
(NS-SEC) reduced method which is primarily based on job occupation, however we acknowledge that 
SES has been defined as a multidimensional construct that is commonly measured in health services 
research as a combination of education, income, and occupation.2 Our rationale for using the NS-SEC 
reduced method, which collapses SES into three potential classes, was primarily based on the observation 
of extremely low cell counts when using alternative NS-SEC methods that collapse SES into eight 
potential classes.  Although job occupation has been indicated as a valid proxy indicator for SES,1 we 
acknowledge that the method used in this analysis did not specifically account for other important 
indicators such as education and income when classifying SES.   We did however observe a trend for 
level of education as a treatment effect modifier providing further support to the SES finding.     
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Comparison to Other Studies 
Comparison of our findings to others should be done with caution as previous studies have not focused on 
evaluating the influence of non-modifiable patient level factors for LBP treatment effect modification and 
have used alternative statistical methods.24, 49, 68  Previous studies have commonly used linear regression 
and incorporated specific thresholds (eg, one standard deviation change from baseline) to aid 
interpretation of the magnitude of treatment effect modification and determine clinically important 
interaction effects. Collectively, many of those studies have found that although most factors predicted 
outcomes regardless of treatment (indicating prognostic capabilities), very few were able to predict 
response to a particular treatment (indicating treatment effect modification).  We used logistic regression 
because the treatment response outcome was dichotomous (RMDQ ≥7) and reported all interactions with 
a p-value ≤0.20 to ensure that all potential modifiers were identified similar to the approach used by 
Gurung et al.,28  however support for treatment effect modification was reduced when using linear 
regression modelling strategies.   
 
Future studies should be designed and powered so they have the ability to distinguish between factors that 
demonstrate prognostic or treatment effect modification capabilities (or both) to further inform clinical 
reasoning.35, 37  We also recognize that for future randomized controlled trials to be adequately powered 
for robust detection of treatment effect modification, the sample size required should be increased at least 
fourfold the required sample size to detect main treatment effects,5, 59 presenting a key challenge to 
research planning, funding and delivery.       
 
Meaning of the Study: Implications for Clinicians 
We have provided preliminary findings for SES, level of education, and number of pain medications as 
potential treatment effect modifiers for LBP prognostic stratified care; however future studies are required 
to confirm these findings prior to changing clinical practice. If our findings are validated in future studies, 
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the outcomes from stratified care may be improved through greater tailoring of stratified care for specific 
patient characteristics. For example, development of an enhanced treatment that better supports and meets 
the needs of low SES patients who are at high risk of persistent disability may provide a beneficial 
treatment option for this population. 
 
Future Research 
Future studies should evaluate complex interactions that may exist between factors identified in this 
analysis and other potentially influential patient characteristics (eg, health literacy, health knowledge, and 
motivation) that may be modified with treatment. For example, the feasibility of developing enhanced 
treatments that better meet the needs of low SES patients has strong potential to inform planning of future 
studies capable of informing best practice. Collectively, findings from this study provide additional 
support for future LBP trials to include SES, education, and pain medications as a means to define 
subgroups and evaluate treatment effect modification. 
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Figure 1. Poor treatment response by socioeconomic status 
Figure 2. Decomposed treatment response by socioeconomic status interactions. 
Figure 3. Poor treatment response by level of education. 
Figure 4. Poor treatment response by number of pain medications. 
Table 1. Baseline characteristics of STarT Back trial participants (n = 851). 
Table 2. Baseline characteristics of participants with poor treatment outcome (RMDQ ≥7) at 4 months. 
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Table 3. Results of separate logistic regression models for 4 month RMDQ (≥7) poor outcome. 
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Figure 1.  
 
 
Figure 2.  
Decomposed Treatment x SES interaction.  
Reference: Control / Low SES 
SES = socioeconomic status; OR = odds ratio; CI = confidence interval. 
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Figure 3.  
 
 
Figure 4.  
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Table 1. Baseline characteristics of STarT Back trial participants (n = 851). 
Variable Total Sample Intervention Control 
Age 
≤44 329 (38.7%) 221 (38.9%) 108 (38.2%) 
45-64 374 (43.9%) 240 (42.3%) 134 (47.3%) 
≥65 148 (17.4%) 107 (18.8%) 41 (14.5%) 
Gender 
Female 500 (58.8%) 330 (58.1%) 170 (60.1%) 
Male 351 (41.2%) 238 (41.9%) 113 (39.9%) 
Education 
Further or higher education 230 (27.1%) 156 (27.5%) 74 (26.2%) 
Other work or non-work related 280 (32.9%) 185 (32.6%) 95 (33.7%) 
Compulsory education 164 (19.3%) 104 (18.3%) 60 (21.3%) 
No qualifications 176 (20.7%) 123 (21.7%) 53 (18.8%) 
Socioeconomic status 
Upper 233 (28.6%) 162 (29.9%) 71 (26.0%) 
Middle 209 (25.6%) 132 (24.4%) 77 (28.2%) 
Lower 373 (45.8%) 248 (45.8%) 125 (45.8%) 
Currently employed 
Yes 524 (61.6%) 350 (61.6%) 174 (61.5%) 
No 327 (38.4%) 218 (38.4%) 109 (38.5%) 
Work satisfaction* 
Satisfied 427 (81.5%) 288 (82.3%) 139 (79.9%) 
Not satisfied 97 (18.5%) 62 (17.7%) 35 (20.1%) 
Duration of symptoms (How long since whole month without pain?) 
< 1 month 151 (17.7%) 97 (17.1%) 54 (19.1%) 
1-3 months 190 (22.3%) 124 (21.8%) 66 (23.3%) 
> 3 months 510 (59.9%) 347 (61.1%) 163 (57.6%) 
Pain medications 
0 223 (26.2%) 136 (23.9%) 87 (30.7%) 
1 to 2 444 (52.2%) 289 (50.9%) 155 (54.8%) 
≥3 184 (21.6%) 143 (25.2%) 41 (14.5%) 
Expectation for recovery at 4-months 
High 342 (40.4%) 222 (39.2%) 120 (42.7%) 
Moderate 384 (45.3%) 261 (46.1%) 133 (43.8%) 
Low 121 (14.3%) 83 (14.7%) 38 (13.5%) 
*Work satisfaction estimates based on participants that were currently employed (n=524). 
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Table 2. Baseline characteristics of participants with poor treatment outcome 
(RMDQ ≥7) at 4 months. 
Variable Treatment Allocation  
 Intervention Control  
Age 
≤44 32 (20.1%) 22 (33.3%) P = .052  
45-64 70 (33.2%) 46 (39.7%) P = .292 
≥65 35 (36.5%) 17 (42.5%) P = .644 
Gender 
Female 85 (31.0%) 53 (39.3%) P = .119 
Male 52 (27.1%) 32 (36.8%) P = .134 
Education 
Further or higher education 23 (19.0%) 18 (30.0%) P = .140 
Other work or non-work related 35 (22.3%) 28 (37.8%) P = .021 
Compulsory education 26 (32.1%) 19 (43.2%) P = .298 
No qualifications 53 (49.5%) 19 (44.2%) P = .684 
Socioeconomic status 
Upper 26 (19.3%) 21 (38.9%) P = .009 
Middle 30 (27.5%) 24 (35.8%) P = .322 
Lower 70 (35.4%) 35 (37.2%) P = .866 
Currently employed 
Yes 57 (20.6%) 44 (32.8%) P = .010 
No 80 (42.3%) 41 (46.6%) P = .588 
Work satisfaction 
Satisfied 48 (20.9%) 33 (30.8%) P = .065 
Not satisfied 9 (19.1%) 11 (40.7%) P = .081 
Duration of symptoms (How long since whole month without pain?) 
< 1 month 23 (28.4%) 16 (40.0%) P = .281 
1-3 months 13 (12.9%) 13 (23.2%) P = .150 
> 3 months 101 (35.6%) 56 (44.4%) P = .114 
Pain medications 
0 18 (17.1%) 13 (18.3%) P = .997 
1 to 2 77 (31.2%) 54 (46.6%) P = .006 
≥3 42 (36.8%) 18 (51.4%) P = .179 
Expectation for recovery at 4-months 
High 32 (16.9%) 26 (28.9%) P = .031 
Moderate 67 (31.9%) 36 (36.7%) P = .483 
Low 36 (55.4%) 23 (71.9%) P = .179 
RMDQ – Roland and Morris Disability Questionnaire.  
% indicates – percent of those that had poor treatment outcome (RMDQ≥7). 
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Table 3. Results of separate logistic regression models for 4 month RMDQ (≥7) poor outcome. 
 Factor Treatment Allocation Factor x Group Term 
Age 1.14 (0.72, 1.80), P=.567 0.46 (0.15, 1.41), P=.173 1.12 (0.65, 1.95), P=.682 
Gender 0.94 (0.50, 1.77), P=.846 0.62 (0.19, 1.96), P=.414 0.95 (0.43, 2.07), P=.890 
Education 1.09 (0.82, 1.45), P=.558 0.28 (0.11, 0.71), P=.008 1.33 (0.94, 1.90), P=.109 
Socioeconomic status 0.87 (0.59, 1.28), P=.474 0.18 (0.06, 0.54), P=.003 1.71 (1.06, 2.77), P=.028 
Employment 1.63 (0.87, 3.06), P=.128 0.44 (0.13, 1.42), P=.169 1.18 (0.54, 2.57), P=.676 
Current status 1.31 (0.59, 2.91), P=.515 0.57 (0.12, 2.59), P=.465 0.96 (0.35, 2.66), P=.934 
Work satisfaction 1.37 (0.53, 3.53), P=.513 0.83 (0.17, 4.09), P=.822 0.68 (0.19, 2.42), P=.554 
Symptom duration 1.58 (1.05, 2.39), P=.029 0.60 (0.16, 2.22), P=.443 0.96 (0.58, 1.60), P=.889 
Medication 1.60 (0.97, 2.62), P=.063 1.36 (0.39, 4.72), P=.634 0.64 (0.35, 1.16), P=.140 
Expectation 1.70 (1.07, 2.69), P=.025 0.35 (0.12, 1.05), P=.062 1.28 (0.72, 2.25), P=.403 
Values are odds ratio (95% confidence intervals) and associated P value for the effect of the factor, the 
main effect of treatment group, and the interaction between factor and treatment group on 4 month 
RMDQ (≥7) poor outcome status. Binary logistic final model estimates (baseline RMDQ included in all 
models). Treatment allocation (reference = control group) 
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Highlights 
• We conducted a secondary analysis to identify treatment-effect modifiers within the STarT 
Back Trial at 4 months follow-up.  
• Socioeconomic status was identified as an effect modifier for disability outcomes with 
education level and number of pain medications meeting criteria for effect modification with 
weaker evidence. 
• We have provided preliminary exploratory findings about characteristics of patients who 
might least likely benefit from prognostic stratified care treatment for low back pain. 
 
